Skip to content
Limula-6.2 Million

Limula raises CHF 6.2 Million

Share this article

Limula raises CHF 6.2 Million in oversubscribed Seed round to develop automated Cell and Gene Therapy manufacturing platform.



The oversubscribed seed round was led by LifeX Ventures, with participation from the founders, Verve Ventures, Zühlke Ventures, Oxford Seed Fund, Lichtsteiner Foundation, W.A. de Vigier Foundation, and a line-up of private individuals who have been supporting Limula’s vision from its inception.

Limula was founded in 2020 by Dr. Yann Pierson, Dr Luc Henry. Dr. Thomas Eaton to deliver a disruptive approach to the ‘ex vivo’ manipulation of cells, based on a novel technology. The trio witnessed that outdated manufacturing methods were a speed bump to the adoption of Cell and Gene Therapy products – like chimeric antigen receptor (CAR) T-cells.

Combining breakthrough discoveries in genetic engineering and medicine led to a revolution in medicine, but boosting the patients’ own cells to produce a dose in a laboratory still requires too many manual steps. Highly skilled labour and sterile infrastructure represent the majority of the costs of a therapy, leading to a price tag of $500’000 or more per dose. As a result, these treatments are inaccessible for a majority of eligible patients.

To combat this, Limula developed a modular solution for on-demand and at-scale manufacturing of cell therapies in a single device. By combining the functionalities of a bioreactor and a centrifuge into one single closed vessel, Limula’s proprietary solution can handle a wide range of volumes and cell numbers, removing transfer steps and therefore limiting stress, losses, and potential contamination.

With potential for scalability, it can be used by cell therapy providers in their transition from pre-clinical evaluation to clinical trials, and later commercial scale manufacturing of clinical-grade cell products.

Luc Henry, co-founder and CEO of Limula said: “Our team is driven by the ambitious goal of developing tools that are based on a fundamentally novel way of manipulating cells outside of the body. Our technology supports manufacturing workflows that are impossible to automate with existing tools. We believe automation is the only route to scalability and digital traceability. These two aspects are keys to unlocking the full potential of Cell and Gene Therapy, making them accessible to the many, not just the few”.

Dr Inaki Berenguer, managing partner at LifeX Ventures said: “We’re thrilled to stand with the Limula team as they reinvent cell and gene therapy manufacturing. It’s evident that production tools have lagged behind scientific and clinical advancements, particularly in terms of price and scalability. Limula’s commitment to addressing these bottlenecks is crucial to enhancing accessibility for patients.”

Looking ahead, Limula will use its new Seed capital to significantly advance the development of the proprietary platform composed of a device and single use consumables, towards meeting good manufacturing practice (GMP) requirements.



Source: press release